



**HAL**  
open science

# PREVALENCE OF DIFFERENT HPV TYPES AND ESTIMATION OF PROGNOSTIC RISK FACTORS BASED ON THE LINEAR ARRAY HPV GENOTYPING TEST

Eleni Papachristou, Vana Sypsa, Dimitrios Paraskevis, Athanasios Gkekas, Ekaterini Politi, Electra Nicolaidou, Ioannis Anifantis, Mina Psychogiou, Artemis Tsitsika, Maria Hadjivassiliou, et al.

► **To cite this version:**

Eleni Papachristou, Vana Sypsa, Dimitrios Paraskevis, Athanasios Gkekas, Ekaterini Politi, et al.. PREVALENCE OF DIFFERENT HPV TYPES AND ESTIMATION OF PROGNOSTIC RISK FACTORS BASED ON THE LINEAR ARRAY HPV GENOTYPING TEST. *Journal of Medical Virology*, 2009, 81 (12), pp.2059. 10.1002/jmv.21639 . hal-00531829

**HAL Id: hal-00531829**

**<https://hal.science/hal-00531829>**

Submitted on 4 Nov 2010

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



**PREVALENCE OF DIFFERENT HPV TYPES AND ESTIMATION  
OF PROGNOSTIC RISK FACTORS BASED ON THE LINEAR  
ARRAY HPV GENOTYPING TEST**

|                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Journal:                      | <i>Journal of Medical Virology</i>                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Manuscript ID:                | JMV-09-1258.R2                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Wiley - Manuscript type:      | Research Article                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Date Submitted by the Author: | 23-Jul-2009                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Complete List of Authors:     | PAPACHRISTOU, ELENI; UNIVERSITY OF ATHENS, DEPARTMENT OF HYGIENE EPIDEMIOLOGY AND MEDICAL STATISTICS<br>SYPSA, VANA<br>PARASKEVIS, DIMITRIOS<br>GKEKAS, ATHANASIOS<br>POLITI, EKATERINI<br>NICOLAIDOU, ELECTRA<br>ANIFANTIS, IOANNIS<br>PSICHOGIOU, MINA<br>TSITSIKA, ARTEMIS<br>HADJIVASSILIOU, MARIA<br>PETRIKKOS, GEORGIOS<br>KATSAMBAS, ANDREAS<br>CREATSAS, GEORGIOS<br>Hatzakis, Angelos; Athens University Medical School, Hygiene and Epidemiology |
| Keywords:                     | HPV genotyping, HPV prevalence, PCR                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                            |



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

**PREVALENCE OF DIFFERENT HPV TYPES AND ESTIMATION OF  
PROGNOSTIC RISK FACTORS BASED ON THE LINEAR ARRAY HPV  
GENOTYPING TEST**

Eleni Papachristou<sup>1</sup>, Vana Sypsa<sup>1</sup>, Dimitrios Paraskevis<sup>1</sup>, Athanasios Gkekas<sup>2</sup>,  
Ekaterini Politi<sup>2</sup>, Electra Nicolaidou<sup>3</sup>, Ioannis Anifantis<sup>4</sup>, Mina Psychogiou<sup>4</sup>,  
Artemis Tsitsika<sup>5</sup>, Maria Hadjivassiliou<sup>3</sup>, Georgios Petrikos<sup>4</sup>, Andreas Katsambas<sup>3</sup>,  
Georgios Creatsas<sup>2</sup>, Angelos Hatzakis<sup>1</sup>.

<sup>1</sup>Department of Hygiene and Epidemiology and Medical Statistics, University of Athens  
School of Medicine, <sup>2</sup>2<sup>nd</sup> Department of Obstetrics and Gynecology, Aretaieion Hospital,  
University of Athens, School of Medicine, <sup>3</sup>Sexually Transmitted Infections Unit, <sup>1</sup>1<sup>st</sup>  
Department of Dermatology and Venereology, University of Athens, School of Medicine,  
A.Syggros Hospital, <sup>4</sup>Infectious Diseases Research Laboratory “G.K Daikos” University of  
Athens, School of Medicine, Laiko General Hospital Athens, <sup>5</sup> Adolescent Health Unit, <sup>2</sup>2<sup>nd</sup>  
Department of Pediatrics, University of Athens School of Medicine, “P.and A. Kyriakou”  
Children’s Hospital, Greece

34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Correspondence to: Angelos Hatzakis  
Department of Hygiene Epidemiology and Medical Statistics,  
Medical School, University of Athens  
Mikras Asias 75, GR-11527,  
Athens, Greece  
E-mail:ahatzak@med.uoa.gr

**Abstract**

The aim of the study was to evaluate the prevalence and risk factors of HPV in a gynecological population attending outpatient clinics using two new molecular tests.

The Amplicor HPV test and the Linear Array HPV Genotyping test (LA) were used for the detection of HPV DNA in 320 women. Multiple logistic regression was used to identify independent prognostic factors of HPV positivity.

The agreement between the two methods in terms of their qualitative results was 89.3% (kappa: 0.63). Based on the LA results, the overall prevalence of HPV DNA was 49.1% (95% CI: 43.5%, 54.7%). The prevalence of high-risk HPV types was 30.3%. The predominant types were HPV-6 (24.8%) and HPV-16 (20.4%). Among women with normal cytology, the prevalence of HPV was much higher in those presenting other findings, such as inflammation, than those without other abnormal findings (49.5% vs. 31.5%). On the basis of multivariate analysis, the risk of HPV infection was higher among women with multiple sexual partners (>3 vs. 1: OR=3.1, 95% CI: (1.5, 7.2)), Pap smear findings (low/high-grade lesions vs. negative: OR=2.8, 95% CI: (1.2, 6.5)), the presence of warts (yes vs. no: OR=3.0, 95% CI: (1.5, 6.3)) and no history of child birth (no vs. yes: OR=2.6, 95% CI: (1.0, 6.7)). Younger age was an additional risk factor for HPV infection with carcinogenic genotypes (OR for 1-year increase =0.93, 95% CI: (0.89, 0.98)).

**Key words:** HPV prevalence, HPV genotyping, PCR

## Introduction

Cervical cancer is the second most frequent female cancer worldwide resulting in about 270,000 deaths annually [Ferlay et al., 2005; Munoz., 2000; Parkin et al., 1990]. The association of HPV infection with the development of cervical cancer and its precursor lesions has been well established [Munoz., 2000; Bosch et al., 2002; Clifford et al., 2003; Wallboomers et al., 1999; Wallin et al., 1999]. Recent studies have shown that HPV DNA can be found in 99.7% of all cervical cancers, with HPV types 16,18,45,31 being the most frequent [Wallboomers et al., 1999; Koutsky et al., 2002]. HPVs are non-enveloped double-stranded DNA viruses which belong to the Papillomaviridae family, which consist of more than 100 different HPV genotypes, 40 of which infect the genital tract [Chan et al., 1995; de Villiers et al., 2004; zur Hausen., 1991] and cause mainly transient infections [Evader et al., 1995; Rosenfeld et al., 1992; Hinchilfe et al., 1995]. Based on the etiological role in the progression to cervical cancer, 15 HPV genotypes have been classified as high risk, 3 genotypes (26,53,66) have been classified as probable high risk, 12 genotypes (such as 6,11 which are detected frequently in benign lesions such as condylomata accuminata) have been classified as low risk and 3 genotypes (34,57,83) are classified as of undetermined risk [Munoz et al., 2003].

Genotyping is, among others, important for epidemiological studies for the evaluation of HPV infections worldwide [van Hamont et al., 2006; Ferenczy et al., 2002; Meier et al., 2006]. The aim of the study was to evaluate the prevalence and risk factors of HPV among women who visited the outpatient clinics of four hospitals of Athens, for gynecological examination and Pap-test, using a linear assay HPV DNA test assessing the 37 most common anogenital HPV genotypes.

## METHODS

### Patients

320 cervical scrapes were collected from November, 2005 until March, 2008 from 320 apparently healthy women 16-71 years of age who attended the gynecological or the infectious diseases outpatient clinic of Aretaieion, A.Syggros, "P&A Kyriakou" Childrens' and Laiko hospitals of Athens, Greece. Many of the women had genital warts, abnormal Pap smears or other vaginal infections. The study was approved by the Institutional Review Board of Athens University Medical School and an informed consent from the patients was obtained.

### Methods

The samples were collected in PreservCyt solution (Cytoc Corporation®, Marlborough, USA) with a Cervex-brush® (Rovers Medical Devices B.V., The Netherlands) and stored at 2-8°C according to the manufacturer's instructions. The cervical scrapes were examined by using two assays available commercially: the Amplicor® HPV test, and the Linear Array HPV Genotyping test (LA) (both from Roche Molecular Systems, Inc., Branchburg, NJ USA). The Amplicor HPV test is a qualitative in vitro test for the detection of 13 high risk HPV genotypes (16,18,31,33,35,39,45,51,52,56,58,59,68) while the LA is a qualitative in vitro test for the detection of 37 anogenital HPV genotypes (including high risk HPVs detected by the Amplicor HPV test) in cervical cells. Both tests are based on four major processes: specimen preparation, PCR amplification of the target DNA, hybridization of the amplified products to oligonucleotide probes and detection of the

1  
2  
3 probe-bound amplified products by colorimetric determination [Gravitt et al., 2000;  
4  
5  
6 Davies et al., 2001].

7  
8 HPV DNA was extracted from the samples using the Amplilute Liquid Media, (Roche  
9  
10 Molecular Systems, Inc., Branchburg, NJ USA) according to the manufacturer's  
11  
12 instructions. The Amplicor HPV test uses a pool of biotinylated primers which  
13  
14 amplify an approximately 165bp sequence within the polymorphic L1 region of the  
15  
16 genome of 13 high risk HPV genotypes.

17  
18  
19  
20 The LA Genotyping test uses a pool of biotinylated primers designed to amplify an  
21  
22 approximately 450 bp sequence within the polymorphic L1 region of the genome of  
23  
24 37 HPV genotypes. An additional 268 primer pair which targets the human  $\beta$ -globin  
25  
26 gene is included in both assays to provide a control for cell adequacy, extraction and  
27  
28 amplification. After completion of the PCR, amplified DNA is denatured and is added  
29  
30 either into wells of a microwell plate which contain either HPV or  $\beta$ -globin probes or  
31  
32 on strips which are covered with HPV and  $\beta$ -globin oligonucleotide probes.  
33  
34

35  
36 Data analysis and epidemiological associations were based on Linear Array HPV  
37  
38 Genotyping test. The prevalence of HPV was estimated as the proportion of women  
39  
40 with HPV DNA positive test and the 95% confidence interval (95% CI) was also  
41  
42 calculated. The chi-squared test or the t-test was used to examine the presence of  
43  
44 association between HPV DNA status and the characteristics of the patient. Multiple  
45  
46 logistic regression was used to identify independent prognostic factors for HPV  
47  
48 positivity.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

### *Study participants*

The characteristics of the women participating in the study are shown in Table 1. Their age ranged from 16-71 years with a mean (SD) of 28.4 (8.7) years. Approximately one third of the women (31 %) had warts and 50.5% reported more than three lifetime sexual partners. The age of first sexual contact ranged from 13-34 years with a mean (SD) of 18.0 (2.6) years. Only 17.3% of the enrolled women had at least one child and 15.1% reported at least one abortion (Table 1).

### *Comparison of the AmpliCor HPV test and the Linear Assay*

The agreement between the two methods in terms of their qualitative results was 89.3% (kappa: 0.63). In one sample it was not possible to obtain a result by AmpliCor HPV test. All AmpliCor HPV negative samples ,except one, were either negative (75.2%) with the LA test or low risk genotypes (24.3%) were found (Table 5).

### *Prevalence of HPV*

Taking into account all 37 genotypes, 157 women (49.1%) were found to be positive for any HPV type (95% Confidence Interval (CI): (43.6%, 54.6%)). Approximately one third of the infections (36.9%) involved only one HPV type while the prevalence of infections with two and three or more types was 33.8% and 29.3%, respectively.

The prevalence (95% CI) of high-risk HPV infections was 30.3% (25.3%, 35.7%).

The genotype which was identified most frequently among infected women was HPV6 (24.8%) followed by HPV16 (20.4%), HPV42 (17.8%), HPV51 (14.7%), HPVCP6108 and HPV31 (12.7%), HPV52 and HPV62 (12.1%), HPV66 (10.2%), HPV53 (8.9%), HPV84 (7.6%), HPV59 and HPV18 (7%), HPV56 and HPV61 (6.4%). (Table 2)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

***Prognostic factors of HPV infection: Univariate analysis***

The prevalence of HPV in women <25, 25-29, 30-34, 35-39 and over 40 years of age was 52.1%, 55.4%, 46.8%, 41.4%, and 29% respectively ( $p=0.104$ ) (Fig.1). The prevalence of HPV increased with increasing number of sexual partners. More specifically, among women with one, two, three and more than three lifetime partners, the prevalence of HPV was 27.4%, 36.2%, 51.1% and 61.1%, respectively ( $p<0.001$ ) (Table 3). According to the Pap test result, the prevalence of HPV was 100% for the high-grade smears (3/3), 62.9% for low-grade (44/70), 33.3% for the Atypical Squamous Cells of Undetermined Significance (ASCUS) smears (10/30) and 31.5% for the negative smears without any other findings (17/54) ( $p=0.001$ ). In negative smears with other findings such as inflammation, trachilitis, fungi and condylomata the prevalence of HPV was 49.5% (51/103) ( $p=0.001$ ) (Table 3).

The prevalence of HPV in women who had external genital warts was higher compared to those without warts (62% and 42.7% respectively,  $p=0.001$ ). Among women who had given at least one birth, the prevalence of HPV was 29.1% (16/55) whereas in those with no births the corresponding rate was 53.6% (141/263), ( $p=0.001$ ). HPV was detected at similar rates in smokers and non-smokers (52.8% and 46.7% respectively,  $p=0.282$ ) (Table 3).

Considering only the high risk HPV genotypes, the detection rates in women <25, 25-29, 30-34, 35-39 and over 40 years of age were 34.7%, 32.6%, 31.9%, 20.7% and 12.9% respectively (Table 3). The prevalence of high risk types in women with one, two, three and more than three lifetime partners was 14.5%, 19.2%, 37.8%, and 37.6% respectively ( $p=0.002$ ). The detection rates of one or more high risk genotypes in high grade, low grade, Atypical Squamous Cells of Undetermined Significance

1  
2  
3 (ASCUS), and negative Pap-smears without any other finding were 100% (3/3), 47.1  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

(ASCUS), and negative Pap-smears without any other finding were 100% (3/3), 47.1  
%( 33/70), 13.3% (4/30) and 14.8 % (8/54) respectively. In negative smears with  
some other findings such as inflammation, trachilitis, fungi and condylomata the  
detection rate was 30% (31/103) ( $p < 0.001$ ). In women who had external genital warts,  
high risk types were detected in 33% (33/100) of women ( $p = 0.409$ ). High risk types  
were detected in 18.2% (10/55) of those who had given at least one birth whereas in  
those without a history of births the detection rate was 33% (87/263), ( $p = 0.029$ ).  
Among smokers, high risk types were detected in 34.2% (55/161) of women and in  
non-smokers the respective rate was 27% (41/152) (Table 3).

#### ***Prognostic factors of HPV infection: Multivariate analysis***

In multiple logistic regression, detection of any HPV was associated with presence of  
genital warts (OR=3.0, 95%CI: 1.5-6.3,  $p = 0.003$ ), multiple sexual partners (>3  
partners vs. 1: OR=3.2, 95%CI: 1.5-7.0  $p = 0.004$ ) and presence of low/high-grade  
lesions (OR=2.8, 95%CI: 1.2-6.5,  $p = 0.014$ ) (Table 4). There was a marginal  
association between the absence of births and risk for HPV, i.e. women reporting no  
births were at higher risk of being HPV positive relative to those with children  
(OR=2.56, 95%CI: 0.99-6.66,  $p = 0.054$ ) (Table 4).

Multiple logistic regression was also used to identify prognostic factors of HPV  
infection with high risk types. Older women had a reduced risk of being positive for a  
high risk HPV type (OR=0.9, 95%CI: 0.9-0.98,  $p = 0.008$ ), while multiple sexual  
partners (3 partners vs.1) increased the risk by four times (OR=4.0, 95%CI: 1.4-12.0,  
 $p = 0.012$ ). In women with low/high-grade lesions the risk of infection with a high risk  
type was increased compared to women with a normal Pap test (OR=5.6, 95% CI:  
2.1-14.5,  $p < 0.001$ ) (Table 4).

## DISCUSSION

This is the first study on HPV prevalence conducted in Greece which is based on an up-to-date laboratory method. The main question was to estimate both the prevalence and the associated risk factors of HPV in a gynecological population attending outpatient clinics using two nucleic acid amplification-based tests.

Our sample allowed the estimation of the prevalence with a precision of 5.5%. To date, data on this topic in the Greek population are very limited. Patients' participation in the study was rather slow and a prolonged period for sample collection would be needed to attain the sample size goal which was 500 patients. The population studied does not represent the general population as it includes women who were attending the clinic for medical advice and treatment for vaginal infections. Of course there were women who underwent cytology testing as a routine examination. It should be noted that in Greece there is no organised screening programme so many women choose to have a Pap test while others had never been tested cytologically until symptoms developed.

The prevalence of the different HPV types was based on the Linear Array test. In addition all the samples were also examined by the Amplicor HPV test in order to evaluate the performance of the two tests. Both tests are based on nucleic acid amplification. The use of the LA results allowed an estimation of the prevalence of any HPV and of high-risk types as well as the associated risk factors.

The agreement between the two methods in terms of their qualitative results was 89.3% (kappa: 0.63). In one sample it was not possible to obtain a result by the Amplicor HPV test (Table 5). All Amplicor HPV negative samples, except one, were either negative (75.2%) by the LA test or identified low risk genotypes (24.3%). This

1  
2  
3 indicates that the Amplicor test could be used as a screening test for high risk HPV  
4  
5 types followed by the LA test which provides information not only on the involved  
6  
7 genotype but also on the persistence with the same genotype, which is a major risk  
8  
9 factor for progression to cervical cancer.  
10  
11

12  
13 In the study by Mo et al (2008) the Amplicor test was compared with the Hybrid  
14  
15 Capture II and since both assays did not differ in terms of sensitivity and specificity  
16  
17 they could be used for the detection of high risk HPV DNA with similar efficacy in  
18  
19 specimens collected in the PreservCyt solution. On the other hand, Sandri et al (2006)  
20  
21 found that the Amplicor test provided a larger number of positive results in women  
22  
23 with normal smears and this difference may be due to the fact that the Hybrid Capture  
24  
25 II is characterized by a signal amplification step.  
26  
27

28  
29 In this study, the prevalence of the HPV types among women attending outpatient  
30  
31 gynecological clinics was found to be 49.1%. When only women with negative Pap  
32  
33 test and the absence of other findings were considered, the corresponding prevalence  
34  
35 was 31.5%. From the limited epidemiological data in Greece, Kroupis et al [2007]  
36  
37 mentioned that the prevalence of HPV in an almost similar study group was 60% with  
38  
39 types 16, 53 and 6 being the most frequent. In women with normal cytology the  
40  
41 respective rate was 23.6%. Panotopoulou et al [2007] found a prevalence of 53.6% of  
42  
43 HPV, with types 11 and 18 being the most frequent. It should be noted that the above  
44  
45 study group differed from the present study as it involved a 10% of women with  
46  
47 Squamous Cell Carcinoma. Nevertheless, in the women with normal cytology of that  
48  
49 study the prevalence of HPV was 26.4%, whereas in another study conducted by  
50  
51 Agorastos et al [1995] for asymptomatic women with normal cytology in Northern  
52  
53 Greece, the respective prevalence was 36.3%. The higher detection rates of HPV  
54  
55 observed in younger women, when compared to older women, falls with increasing  
56  
57  
58  
59  
60

1  
2  
3 age and this finding is in agreement with many other published studies [Jacobs et al.,  
4 2000; De Roda et al., 1995; Cuzick et al., 1999]. This can be a result of either reduced  
5  
6 sexual activity and less high risk behavior factors such as unprotected sex or acquired  
7  
8 immunity to HPV from past exposure [Burk et al., 1996a;]. Furthermore, older  
9  
10 women were also found to have a reduced risk of infection with a carcinogenic HPV  
11  
12 type.  
13  
14

15  
16  
17 It is known that there is a positive association between the number of sexual partners  
18  
19 and the infection with HPV [Burk et al., 1996b; Tarkowski et al., 2004]. In the  
20  
21 present study, multiparity increased the risk of harboring HPV by 3-4 times when  
22  
23 compared with the women who declared a single partner.  
24  
25

26  
27 The presence of carcinogenic HPV types is greater in abnormal smears and many  
28  
29 studies have demonstrated that the prevalence of HPV increases in parallel with the  
30  
31 severity of cervical lesions [Jacobs et al., 2000; Grce et al., 2001; Evans et al., 2006].  
32  
33 In terms of finding of HPV in normal smears, the results of the current study suggest  
34  
35 that in women with negative smears but with inflammation, trachilitis, fungi and  
36  
37 genital warts, the prevalence of high risk HPV types was greater than in those with  
38  
39 negative smears without any other findings. In previous studies [Singh et al., 1995;  
40  
41 Parashari et al., 1995] negative smears with inflammation were suspicious for HPV  
42  
43 infection, whereas in the study of Arora et al., [2005] a 10% of women who had a  
44  
45 negative Pap smear with inflammation had high-risk types HPV16 and 18.  
46  
47  
48

49  
50 The risk of detecting HPV in the cervix was three times higher when patients had  
51  
52 genital warts. Other studies show that women with genital warts may be at an  
53  
54 increased risk for harboring high risk HPV types [Mosciki et al., 2001] and have a  
55  
56 Cervical Intraepithelial Neoplasia risk up to six times greater [Ward et al., 1994] than  
57  
58  
59  
60

1  
2  
3 women in the general population [Sellors et al., 2000] since external genital warts may  
4  
5 be a marker of a relative deficiency in immune response [Shlay et al., 1998].  
6  
7

8 The absence of births in a woman doubles approximately the risk of infection with  
9  
10 HPV. Several studies [Veress et al., 1996; Fife et al., 1996; Fife et al., 1999;  
11  
12 Nobbenhuis et al., 2002] show that during pregnancy the rate of HPV detection  
13  
14 increases due to hormonal changes or immunological factors which lead to activation  
15  
16 of HPV. This activation may trigger the immune system to respond and thus clear the  
17  
18 virus.  
19  
20

21  
22 Smoking did not seem to influence the prevalence of HPV in this and other studies  
23  
24 [Tarkowski et al., 2004; Deacon et al., 2000]. Other studies show that smoking is not  
25  
26 only associated with an increased prevalence of HPV, but also that the prevalence of  
27  
28 HPV increases with smoking [Vaccarella et al., 2008;] whereas Hildesheim et al  
29  
30 [1994] and Ho et al [1998] found that smoking was a potentially protective factor  
31  
32 against persistent HPV infection.  
33  
34

35  
36 The availability of HPV vaccines may change the future epidemiology of HPV. It  
37  
38 would be of interest to monitor this natural experiment by periodical studies on the  
39  
40 prevalence of HPV types in cervical cells.  
41  
42  
43  
44

45  
46 **ACKNOWLEDGEMENTS** The authors would like to thank Roche Molecular Systems  
47  
48 for providing the test kits and the Hellenic Scientific Society for the Study of AIDS  
49  
50 and Sexually Transmitted Diseases for financial support.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**REFERENCES**

- 1  
2  
3  
4  
5  
6 Agorastos T, Bontis J, Lambropoulos AF, Constantinidis TC, Nasioutziki M, Tagou  
7  
8 C, Katsouyiannopoulos V.1995.Epidemiology of human papillomavirus infection in  
9  
10 Greek asymptomatic women. *Eur J Cancer Prev*: 4:159-67  
11  
12  
13 Arora R, Kumar A, Prusty K, Kailash U, Batra S, Das BC.2005. Prevalence of high-  
14  
15 risk human papillomavirus (HR-HPV) types 16 and 18 in healthy women with  
16  
17 cytologically negative Pap smear. *Eur J of Obstetr and Reproduc Biol*: 121:104-109  
18  
19  
20 Bosch FX, Lorinez A, Munoz N, Meijer CJ, Shah KV.2002The causal relation  
21  
22 between human papillomavirus and cervical cancer. *J Clin Pathol*: 55:244-265  
23  
24  
25 Burk RD, Kelly P, Feldman J, Vermund SH, DeHovitz JA, Landesman  
26  
27 SH.1996.Declining prevalence of cervicographical human papillomavirus infection  
28  
29 with age is independent of other risk factors. *Sex Transm Dis*: 23:333-41  
30  
31  
32 Burk RD, Ho GY, Beardsley L, Lempa M, Peters M, Bierman R.1996.Sexual  
33  
34 behavior and partner characteristics are the predominant risk factors for genital human  
35  
36 papillomavirus infection in young women. *J Infect Dis* : 174:679-89  
37  
38  
39 Chan SY, Delius H, Halpern AL, Bernard HU.1995 Analysis of genomic sequences of  
40  
41 95 papillomavirus types: uniting typing, phylogeny and taxonomy. *J Virol*: 69: 3074-  
42  
43 3083  
44  
45  
46 Clifford GM., Smith JS, Plummer M, Munoz N, Franceschi S. 2003Human  
47  
48 papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. *Br J*  
49  
50 *Cancer*: 88:63-73  
51  
52  
53 Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK,  
54  
55 Krausz T, Soutter P.1999.HPV testing in primary screening of older women. *Br J*  
56  
57 *Cancer*: 81:554-8  
58  
59  
60

- 1  
2  
3 Davies P, Kornegay J, Iftner T. Current methods of testing for human papillomavirus.  
4  
5 2001. *Best Practice and Research Clinical Obstetrics and Gynaecology*: 15:677-700  
6  
7  
8 De Roda Husman AM, Walboomers JM, Hopman E, Bleker OP, Helmerhorst TH,  
9  
10 Rozendaal L, Voorhorst FJ, Meijer CJ.1995. HPV prevalence in cytomorphologically  
11  
12 normal cervical scrapes of pregnant women as determined by PCR: the age-related  
13  
14 pattern. *J Med Virol*: 46:97-192  
15  
16  
17 de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen  
18  
19 H.2004. Classification of papillomaviruses. *Virology*: 324:17-27  
20  
21  
22 Deacon JM, Evans CD, Yule R, Desai M, Taylor C, Peto J.2000. Sexual behavior and  
23  
24 smoking as determinants of cervical HPV infection and CIN3 among those infected:a  
25  
26 case-control study nested within the Manchester cohort. *Br J Cancer*: 83: 1565-1572  
27  
28  
29 Evader M, Edlund K, Gustafsson A, Jonsson M, Karlsson R, Rylander E, Wadell G.  
30  
31 1995. Human papillomavirus infection is transient in young women: a population-  
32  
33 based cohort study. *J Infect Dis* : 171 :1026-30  
34  
35  
36 Evans FM, Adamson CS.-C, Papillo JL, St John TL, Leiman G, Cooper K.2006  
37  
38 Distribution of human papillomavirus types in Thin-Prep Papanicolaou Tests  
39  
40 according to the Bethesda 2001 terminology and correlations with patient age and  
41  
42 biopsy outcomes. *Cancer*: 106:1054-64  
43  
44  
45 Ferenczy A, Franco EL.2002. Persistent human papillomavirus infection and cervical  
46  
47 neoplasia. *Lancet Oncol*: 3: 11-16  
48  
49  
50 Ferlay J, Bray F, Pisani P, Parkin DM. 2005. GLOBOCAN 2002: cancer incidence,  
51  
52 mortality and prevalence worldwide, version 2.0. IARC Cancer Base No.5 IARC  
53  
54 Press, Lyon, France [online] <http://www-depdb.iarc.fr/globocan/GLOBOframe.htm>.  
55  
56  
57  
58  
59  
60



1  
2  
3 Fife KH, Katz BP, Roush J, Handy VD, Brown DR, Hansell R.1996.Cancer-  
4 associated human papillomavirus types are selectively increased in the cervix of  
5 women in the first trimester of pregnancy. *Am J Obstet Gynecol* :174:1487-1493  
6  
7

8  
9 Fife KH, Katz BP, Brizendine EJ, Brown DR.1999.Cervical human papillomavirus  
10 deoxyribonucleic acid persists throughout pregnancy and decreases in the postpartum  
11 period. *Am J Obstet Gynecol* :180:1110-1114  
12  
13

14  
15 Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman  
16 MH, Scott DR, Apple RJ.2000.Improved amplification of genital human  
17 papillomaviruses. *J Clin Microbiol* : 38 :357-361  
18  
19

20  
21 Grce M, Husnjak K, Magdic'L, Zlacki M, Lucac J, Fistonc'I, Sikanic'-Dugic' N,  
22 Pavelic' K.2001.Evaluation of genital human papillomavirus infections by  
23 polymerase chain reaction among Croatian women. *Anticancer Res*: 21:579-84  
24  
25

26  
27 Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR,  
28 Rush BB, Lawler P, Sherman ME et al.1994.Persistence of type specific human  
29 papillomavirus infection among cytologically normal women. *J Infect Dis* : 169:235-  
30 40  
31  
32

33  
34 Hinchliffe SA, van Velzen D, Korporaal H, Kolk PL, Boon ME.1995Transience of  
35 cervical HPV infection in sexually active, young women with normal cervicovaginal  
36 cytology. *Br J Cancer*: 72:943-5  
37  
38

39  
40 Ho YFG, Bierman R, Beardsley L, Chang JC, Burk DR.1998. Natural history of  
41 cervicovaginal papillomavirus infection in young women. *N Engl J Med*: 338:423-8  
42  
43

44  
45 Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Franssen-  
46 Daalmeijer N, Meijer CJ.2000.Distribution of 37 mucosotropic HPV types in women  
47 with cytologically normal cervical smears: the age –related patterns for high-risk and  
48 low-risk types. *Int J Cancer*: 87:221-227  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini  
4 LM, Jansen KU. 2002. A controlled trial of a human papillomavirus type 16 vaccine.  
5  
6 N Engl J Med: 347:1645-51  
7

8  
9 Kroupis C, Thomopoulou G, Papathomas TG, Vourlidis N, Lazaris AC.2007.  
10  
11 Population-based study of human papillomavirus infection and cervical neoplasia in  
12  
13 Athens, Greece Epidemiol Infect : 135:943-950  
14  
15

16  
17 Meijer CJ, Snijders PJ, Castle PE. 2006. Clinical utility of HPV genotyping.  
18  
19 Gynecol Oncol: 103: 12-17  
20  
21

22 Mo LZ, Monnier-Benoit S, Kantelip B, Petitjean, Riethmuller D, Pretet JL, Mouglin  
23  
24 C.2008. Comparison of AMPLICOR and Hybrid Capture II assays for high risk HPV  
25  
26 detection in normal and abnormal liquid-based cytology: Use of INNO-LiPA  
27  
28 Genotyping assay to screen the discordant results. J Clin Virol:41:104-110  
29  
30

31 Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, Miller S, Clayton L,  
32  
33 Farhat S, Broering J, Darragh T, Palefsky J.2001.Risks for incident human  
34  
35 papillomavirus infection and low grade squamous intraepithelial lesion development  
36  
37 in young females. JAMA: 285:2995-3002  
38  
39

40  
41 Munoz, N., 2000.Human papillomavirus and cancer: the epidemiological evidence  
42  
43 J Clin Virol 2000; 19:1-5  
44  
45

46 Munoz N, Bosch FX, de Sanjose S, Herrero R, Castella X, Shah KV, Snijders PJ,  
47  
48 Meijer CJ.2003 Epidemiologic classification of human papillomavirus types  
49  
50 associated with cervical cancer. N Engl J Med: 348:518-527  
51  
52

53 Nobbenhuis MAE, Helmerhorst TJM, van den Brule AJC, Rozendaal L, Bezemer PD,  
54  
55 Voorhorst FJ, Meijer CJLM.2002 High-risk human papillomavirus clearance in  
56  
57 pregnant women: trends for lower clearance during pregnancy with a catch-up  
58  
59 postpartum. Br J Cancer: 87:75-80  
60

- 1  
2  
3 Panotopoulou E, Tserkazoglou A, Kouvousi M, Tsiaousi I, Chatzieleftheriou G,  
4  
5 Daskalopoulou D, Magiakos D. 2007. Prevalence of human papillomavirus types 6,  
6  
7 11,16,18,31 and 33 in a cohort of Greek women. *J Med Virol* :79:1898-1905  
8  
9  
10 Parashari A, Singh V, Gupta MM, Satyanarayana L, Chattopadhyaya D, Sodhani P,  
11  
12 Sehgal A.1995. Significance of inflammatory cervical smears. *APMIS*. 103:273-278  
13  
14  
15 Parkin DM, Pisani P, Ferlay J. 1999 Estimates of the worldwide incidence of 25  
16  
17 major cancers in 1990. *Int. J. Cancer*: 80:827-841  
18  
19  
20 Rosenfeld WD, Rose E, Vermund SH, Schreiber K, Burk RD.1992.Follow-up  
21  
22 evaluation of cervicographical human papillomavirus infection in adolescents. *J*  
23  
24 *Pediatr*: 121:307-311  
25  
26  
27 Sandri TM, Lentati P, Benini E, Dell'Orto P, Zorzino L, Carozzi MF, Maisonneuve P,  
28  
29 Passerini R, Salvatici M, Casadio C, Boveri S, Sideri M.2006. Comparison of the  
30  
31 Digene HC2 Assay and the Roche AMPLICOR Human Papillomavirus (HPV) Test  
32  
33 for Detection of High-Risk HPV Genotypes in Cervical Samples. *J Clin Microb*:  
34  
35 44:2141-2146  
36  
37  
38 Sellors JW, Mahony JB, Kaczorowski J, Lytwyn A, Bangura H, Chang S, Lorincz A,  
39  
40 Dalby DM, Janjusevic V, Keller JL.2000. Prevalence and predictors of human  
41  
42 papillomavirus infection in women in Ontario, Canada. *CMAJ*: 163:503-508.  
43  
44 Available:[www.cma.ca/cmaj/vol-163/issue-5/0503.htm](http://www.cma.ca/cmaj/vol-163/issue-5/0503.htm)  
45  
46  
47  
48 Shlay JC, McGill WL, Masloboeva HA, Douglas JM Jr.1998.Pap smear screening in  
49  
50 an urban STD clinic. *Sex Transm Dis*: 25:468-75  
51  
52  
53 Singh V, Gupta MM, Satyanarayana L, Parashari A, Sehgal A, Chattopadhyaya D,  
54  
55 Sodhani P.1995. Association between reproductive tract infections and cervical  
56  
57 inflammatory epithelial changes. *Sex Transm Dis*: 22:25-30  
58  
59  
60

1  
2  
3 Tarkowski TA, Koumans EH, Sawyer M, Pierce A, Black CM, Papp JR, Markowitz  
4 L, Unger ER.2004 .Epidemiology of human papillomavirus and abnormal cytologic  
5 test results in an urban adolescent population. J Infect Dis : 189: 46-50  
6  
7

8  
9  
10 Vaccarella S, Hieu NT, Ferreccio C, et al IARC HPV Prevalence Surveys (IHPS)  
11 Study Group. Smoking and human papillomavirus infection: pooled analysis of the  
12 International Agency for Research on Cancer HPV Prevalence Surveys. Int J  
13 Epidemiol 2008; 37:536-546  
14

15  
16  
17 Van Hamont D, van Ham Maaïke APC, Bakkers Judith MJE, Massuger Leon FAG,  
18 Melches Willem JG.2006 Evaluation of the SPF<sub>10</sub> –INNOLiPA Human  
19 Papillomavirus (HPV) Genotyping Test and the Roche Linear Array HPV Genotyping  
20 Test. J Clin Microbiol: 44:3122-3129.  
21  
22

23  
24  
25 Veress G, Csiky-Meszaros T, Konya J, Czegledy J, Gergely L.1996. Follow-up of  
26 human papillomavirus (HPV) DNA and local anti- HPV antibodies in cytologically  
27 normal pregnant women. Med Microbiol Immunol.1996: 185:139-44  
28

29  
30  
31 Wallboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah  
32 KV.1999.Human papillomavirus is a necessary cause of invasive cervical cancer  
33 worldwide. J Pathol: 189: 12-19  
34

35  
36  
37 Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, Hallmans G,  
38 Dillner J.1999.Type-specific persistence of human papillomavirus DNA before the  
39 development of invasive cervical cancer.  
40  
41

42  
43  
44 N Engl J Med.:341: 1633-1638  
45

46  
47  
48 Ward KA, Lowry BE, Houston JR, Maw RD.1994.Cervical epithelial abnormalities in  
49 females with and without genital warts. Int J STD AIDS: 5:380-1  
50

51  
52  
53 Zur Hausen H.1991 Human papillomaviruses in the pathogenesis of anogenital  
54 cancer. Virology: 184:9-13  
55  
56  
57  
58  
59  
60

Table 1: Characteristics of 320 healthy women with cervical scrapes.

|                                                 |             |
|-------------------------------------------------|-------------|
| <b>AGE (years)</b>                              |             |
| <25                                             | 121 (37.8%) |
| 25-29                                           | 92 (28.8%)  |
| 30-34                                           | 47 (14.7%)  |
| 35-39                                           | 29 (9.1%)   |
| 40+                                             | 31 (9.7%)   |
| <b>NUMBER OF LIFETIME SEXUAL PARTNERS, n(%)</b> |             |
| 1                                               | 62 (19.9%)  |
| 2                                               | 47 (15.1%)  |
| 3                                               | 45 (14.5%)  |
| >3                                              | 157 (50.5%) |
| <b>NUMBER OF DELIVERIES, n(%)</b>               |             |
| 0                                               | 263 (82.7%) |
| 1                                               | 25 (7.9%)   |
| 2                                               | 23 (7.2%)   |
| 3                                               | 7 (2.2%)    |
| <b>NUMBER OF MISCARRIAGES, n (%)</b>            |             |
| 0                                               | 304 (95.6%) |
| 1                                               | 9 (2.8%)    |
| 2                                               | 2 (0.6%)    |
| 3                                               | 3 (0.9%)    |
| <b>NUMBER OF ABORTIONS, n (%)</b>               |             |
| 0                                               | 270 (84.9%) |
| 1                                               | 32 (10.1%)  |
| 2                                               | 10 (3.1%)   |
| 3                                               | 4 (1.3%)    |
| 4                                               | 2 (0.6%)    |
| <b>PRESENCE OF WARTS, n (%)</b>                 |             |
| NO                                              | 218 (69.0%) |
| YES                                             | 100 (31.0%) |
| <b>SMOKING, n (%)</b>                           |             |
| NO                                              | 152 (49.0%) |
| YES                                             | 161 (51.0%) |
| <b>AGE OF FIRST SEXUAL CONTACT</b>              |             |
| Mean (SD)                                       | 18 (2.6)    |
| Range                                           | 13-34       |

Table 2. Prevalence of HPV types in single and any infections

| HPV type | Single infections<br>(N=58) | Any infection<br>(N=157) |
|----------|-----------------------------|--------------------------|
| 6        | 15.5%                       | 24.8%                    |
| 11       | 0.0%                        | 0.6%                     |
| 16       | 15.5%                       | 20.4%                    |
| 18       | 1.7%                        | 7.0%                     |
| 26       | 0.0%                        | 0.0%                     |
| 31       | 12.1%                       | 12.7%                    |
| 33       | 0.0%                        | 2.6%                     |
| 35       | 0.0%                        | 1.9%                     |
| 39       | 0.0%                        | 2.6%                     |
| 40       | 0.0%                        | 0.0%                     |
| 42       | 5.2%                        | 17.8%                    |
| 45       | 0.0%                        | 0.6%                     |
| 51       | 5.2%                        | 14.7%                    |
| 52       | 3.5%                        | 12.1%                    |
| 53       | 1.7%                        | 8.9%                     |
| 54       | 1.7%                        | 3.2%                     |
| 55       | 3.5%                        | 3.2%                     |
| 56       | 1.7%                        | 6.4%                     |
| 58       | 0.0%                        | 4.5%                     |
| 59       | 5.2%                        | 7.0%                     |
| 61       | 1.7%                        | 6.4%                     |
| 62       | 3.5%                        | 12.1%                    |
| 64       | 0.0%                        | 1.3%                     |
| 66       | 5.2%                        | 10.2%                    |
| 67       | 3.5%                        | 5.7%                     |
| 68       | 1.7%                        | 3.8%                     |
| 69       | 0.0%                        | 0.6%                     |
| 70       | 1.7%                        | 0.6%                     |
| 71       | 0.0%                        | 0.6%                     |
| 72       | 0.0%                        | 0.6%                     |
| 73       | 0.0%                        | 4.5%                     |
| 82       | 0.0%                        | 0.0%                     |
| 81       | 0.0%                        | 3.8%                     |
| 83       | 0.0%                        | 3.2%                     |
| 84       | 5.2%                        | 7.6%                     |
| IS39     | 0.0%                        | 0.6%                     |
| CP6108   | 5.2%                        | 12.7%                    |

Table 3: Univariate associations between potential risk factors and HPV or high risk prevalence of HPV.

| PROGNOSTIC FACTORS                     | N   | HPV (+) (any type) |        | HPV (+) (high risk types) |        |
|----------------------------------------|-----|--------------------|--------|---------------------------|--------|
|                                        |     | n(%)               | P      | n (%)                     | P      |
| <b>AGE</b>                             |     |                    |        |                           |        |
| <25                                    | 121 | 63 (52.1)          | 0.104  | 42 (34.7)                 | 0.253  |
| 25-29                                  | 92  | 51 (55.4)          |        | 30 (32.6)                 |        |
| 30-34                                  | 47  | 22 (46.8)          |        | 15 (31.9)                 |        |
| 35-39                                  | 29  | 11 (41.4)          |        | 6 (20.7)                  |        |
| 40+                                    | 31  | 9 (29.0)           |        | 4 (12.9)                  |        |
| <b>No. OF LIFETIME SEXUAL PARTNERS</b> |     |                    |        |                           |        |
| 1                                      | 62  | 17 (27.4)          | <0.001 | 9 (14.5)                  | 0.002  |
| 2                                      | 47  | 17 (36.2)          |        | 9 (19.1)                  |        |
| 3                                      | 45  | 23 (51.1)          |        | 17 (37.8)                 |        |
| >3                                     | 157 | 96 (61.1)          |        | 59 (37.6)                 |        |
| <b>PAP-TEST</b>                        |     |                    |        |                           |        |
| Negative                               | 54  | 17 (31.5)          | 0.001  | 8 (14.8)                  | <0.001 |
| Negative+other                         | 103 | 51 (49.5)          |        | 31 (30.1)                 |        |
| ASCUS <sup>*</sup>                     | 30  | 10 (33.3)          |        | 4 (13.3)                  |        |
| LGSIL <sup>†</sup>                     | 70  | 44 (62.9)          |        | 33 (47.1)                 |        |
| HGSIL <sup>‡</sup>                     | 3   | 3 (100.0)          |        | 3 (100.0)                 |        |
| <b>WARTS</b>                           |     |                    |        |                           |        |
| NO                                     | 218 | 93 (42.7)          | 0.001  | 62 (28.4)                 | 0.409  |
| YES                                    | 100 | 62 (62.0)          |        | 33 (33.0)                 |        |
| <b>DELIVERIES</b>                      |     |                    |        |                           |        |
| NO                                     | 263 | 141 (53.6)         | 0.001  | 87 (33.1)                 | 0.029  |
| YES                                    | 55  | 16 (29.1)          |        | 10 (18.2)                 |        |
| <b>SMOKING</b>                         |     |                    |        |                           |        |
| NO                                     | 152 | 71 (46.7)          | 0.282  | 41 (26.1)                 | 0.168  |
| YES                                    | 161 | 85 (52.8)          |        | 55 (34.1)                 |        |

\* ASCUS: Atypical Squamous Cells of Undetermined Significance

† LGSIL: Low Grade Squamous Intraepithelial Lesion

‡ HGSIL: High Grade Squamous Intraepithelial Lesion

Table 4: Multiple logistic regression model: Prognostic factors of HPV infection (any infection and high risk HPV)

|                                         | ANY HPV |             |       | High Risk HPV |              |        |
|-----------------------------------------|---------|-------------|-------|---------------|--------------|--------|
|                                         | OR      | 95% CI      | P     | OR            | 95% CI       | P      |
| Age(/year)                              | 0.97    | (0.93,1.02) | 0.275 | 0.93          | (0.89,0.98)  | 0.008  |
| <b>Number of lifetime sex. partners</b> |         |             |       |               |              |        |
| <b>2 vs. 1</b>                          | 1.20    | (0.46,3.14) | 0.710 | 1.50          | (0.49,4.55)  | 0.473  |
| <b>3 vs 1</b>                           | 2.27    | (0.86,6.00) | 0.098 | 4.04          | (1.36,12.01) | 0.012  |
| <b>&gt;3 vs 1</b>                       | 3.19    | (1.46,7.01) | 0.004 | 2.92          | (1.19,7.15)  | 0.019  |
| <b>Pap-test</b>                         |         |             |       |               |              |        |
| <b>Ascus/Negative</b>                   | 0.70    | (0.24,1.99) | 0.503 | 0.86          | (0.22,3.26)  | 0.819  |
| <b>Negative+other</b>                   |         |             |       |               |              |        |
| <b>Finding/Negative</b>                 | 1.40    | (0.64,3.10) | 0.401 | 2.43          | (0.98,5.98)  | 0.054  |
| <b>LGSIL,HGSIL/Negative</b>             | 2.84    | (1.24,6.52) | 0.014 | 5.62          | (2.17,14.52) | <0.001 |
| <b>Warts (Yes/No)</b>                   | 3.02    | (1.46,6.27) | 0.003 |               |              |        |
| <b>Deliveries (No/Yes)</b>              | 2.56    | (0.99,6.66) | 0.054 |               |              |        |

ASCUS:Atypical Squamous Cells of Undetermined Significance

LGSIL:Low Grade Squamous Intraepithelial Lesion

HGSIL:High Grade Squamous Intraepithelial Lesion



Table 5: Comparative performance between the Linear Array and Amplicor HPV test on 319 samples.

| <b>LINEAR ARRAY</b> | <b>AMPLICOR (+)</b> | <b>AMPLICOR (-)</b> | <b>TOTAL</b> |
|---------------------|---------------------|---------------------|--------------|
| High risk           | 96 (82.1%)          | 1 (0.5%)            | 97           |
| Low risk            | 12 (10.3%)          | 49 (24.3%)          | 61           |
| Negative            | 9 (7.6%)            | 152 (75.2%)         | 161          |
| <b>TOTAL</b>        | 117                 | 202                 | 319          |

Figure 1. Prevalence of HPV according to age

